LP
MRNS

LMR Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

LMR Partners’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-120,000
Closed -$1.08M – 1385
2024
Q1 		$1.08M Buy
+120,000
New +$1.17M 0.01% 666

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LMR Partners's MRNS Position: Q2 2023 in Review

LMR Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2023, closing a stake of 35,639 shares — an estimated $246K sold.

LMR Partners first reported a position in MRNS in Q2 2022 and held it in 3 quarters. The position peaked at $246K in Q1 2023. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

  • LMR Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 35,639 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $246K.
  • LMR Partners first reported a position in Marinus Pharmaceuticals, Inc in Q2 2022 and held it in 3 quarters.
  • LMR Partners's Marinus Pharmaceuticals, Inc position peaked at $246K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.